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Abstract
It has been more than 50 years since antinuclear antibodies were first discovered and found to be
associated with connective tissue diseases. Since then different methods have been described and
used for their detection or confirmation. For many decades immunofluorescent antinuclear
antibody test has been the "gold standard" in the diagnosis of these disorders. However to increase
the sensitivity and specificity of antinuclear antibody detection further approaches were explored.
Today a battery of newer techniques are available some of which are now considered better and
are competing with the older methods. This article provides an overview on advancement in
antinuclear antibody detection methods, their future prospects, advantages, disadvantages and
guidelines for use of these tests.
Review
Connective tissue diseases (CTD) are a group of autoim-
mune disorders which are characterized by presence of
antinuclear antibodies (ANA) in the blood of patients.
ANA are a specific class of autoantibodies that have the
capability of binding and destroying certain structures
within the nucleus of the cells [1]. Although lower
amounts of these antibodies can be seen in the normal
population as well, a spurt in titers is seen in patients of
CTD. Not only are these antibodies involved in the dis-
ease pathogenesis, but they also constitute the basis for
diagnosis and treatment of CTD. Their detection with
high sensitivity and specificity is therefore of utmost
importance. Various detection methods are in use and
there is continuous pouring of newer techniques to facili-
tate diagnosis and therapeutic monitoring in CTD
patients. In this review we have discussed in brief how
ANA were discovered and found to be associated with
CTD. This article also gives an overview on advancement
in various ANA detection methods, their future prospects
along with advantages, disadvantages and guidelines for
use of these tests.
Historical aspects of ANA
In 1941, Klemperer, Pollack and Baehr first described sys-
temic lupus erythematosus (SLE) as one of the CTD [2].
Then in 1948 Malcom Hargrave, Helen Richmond and the
medical resident Robert Morton noted the presence of
previously unknown cells in the bone marrow of a patient
with SLE. They called these LE cells and described them as
mature polymorphonuclear leukocytes which had phago-
cytosed the liberated nuclear material of another leuko-
cyte [3]. This extremely important discovery laid the
foundation of research for ANA. Since then, ANA has been
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divided into specific subtypes based on the nuclear or
cytoplasmic component they attack i.e. anti-DNA, anti-
histone etc.
ANA – the two broad subtypes
Presently the ANA have been categorized in to 2 main
groups:
Autoantibodies to DNA and histones
These include antibodies against single and double-
stranded DNA (dsDNA) discovered way back in 1957. Sig-
nificant levels of anti-dsDNA antibodies are considered to
be confirmatory in diagnosis of SLE. This was followed by
detection of anti-histone antibodies in 1971 which are
indicative of drug-induced SLE [4-8].
Autoantibodies to extractable nuclear antigens (ENA)
Besides DNA and histones, autoantibodies may also target
other nuclear antigens. These nuclear antigens were
named ENA as originally they were extracted from the
nuclei with saline [8]. Autoantibody to Smith antigen
(Sm) which is considered to be specific for SLE was the
first anti-ENA detected in 1966 [9]. Thereafter further sub-
types of ENA i.e. ribonucleoproteins (RNP), SSA/Ro, or
SSB/La, Scl-70, Jo-1 and PM1 were more clearly identified
[10-17]. Although most of these ENA are disease specific,
still a significant overlap exists. The sensitivity and specif-
icity also varies depending upon the type of underlying
CTD. A list of clinically important ANA with their sensitiv-
ity and specificity of identifying an autoimmune disorder
can be seen in table 1[18,19].
In the last few years many other autoantibodies like topoi-
somerase-I (Topo-I), centromere protein (CENP)-B, RNA-
polymerase I-III (RNA-pol I-III), MU, TM, Ku, Mi-2, RA33
etc. have also been described. While of scientific interest,
typing of many of these antibodies has not found its way
in to the clinical practice. Certain autoantibodies against
cytoplasmic and cell membrane components though
present are less relevant in diagnostics [20,21].
Techniques for ANA detection
Presence of autoantibodies in the sera of the patient con-
stitutes one of the criteria used for diagnosis of CTD (table
2). Besides clinical diagnosis the ANA subtyping also
helps in identifying a specific CTD [22]. Although a bat-
tery of laboratory tests are available for ANA detection
indirect immunofluorescence antinuclear antibody test
(IF-ANA) and enzyme immunoassay (EIA)/enzyme
linked immunosorbent assay (ELISA) are commonly used
in day to day practice. Some of them are considered out-
dated while others like flowcytometry and recently intro-
duced nanotechnology involving antigen arrays are still in
experimental stages.
IF-ANA: The standard ANA testing technique
Before development of IF-ANA test, LE cell preparation
was the only method used for diagnosis of SLE. IF-ANA
was designed by George Friou in 1957 [23]. Since then it
has been the most widely used test for diagnosis of CTD.
It is inexpensive and easy to perform, with high sensitivity
and specificity [24]. The test detects the presence of ANA
in the blood of the patient which adhere to reagent test
cells (substrate), forming distinct fluorescence patterns
that are associated with certain autoimmune diseases. Ini-
tially different substrates like tissue sections, desquamated
cells, chicken erythrocytes and HeLa cells were tried but
later on tissue sections using rat liver or a composite
multiblock substrate (mouse stomach, rat liver and kid-
ney) became the standard substrate. In 1975 HEp-2 cells
were introduced which have further increased the sensitiv-
ity of the test. These are the cultured cells of laryngeal
Table 1: Sensitivity and specificity of ANA and its clinically important subtypes [18,19]
Autoantibodies Associated CTD Sensitivity Specificity
ANA SLE 93 57
Sjogren's syndrome 48 52
SS 85 54
PM/dermatomyositis 61 63
Raynaud phenomena 64 41
Specific ANA
Anti-dsDNA SLE 57 97
Anti-Sm SLE 25–30 High*
Anti-SSA/Ro Sjogren's syndrome, subacute cutaneous SLE, Neonatal lupus syndrome 8–70 87
Anti-SSB/La Sjogren's syndrome, subacute cutaneous SLE, Neonatal lupus syndrome 16–40 94
Anti-U3-RNP SS 12 96
Anticentromere Limited cutaneous SS 65 99.9
Scl-70 SS 20 100
Jo-1 PM 30 95
* Precise data not available.Diagnostic Pathology 2009, 4:1 http://www.diagnosticpathology.org/content/4/1/1
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squamous cell carcinoma and are available commercially
in the form of prefixed on glass slides. Majority of the lab-
oratories around the world are now using HEp-2 cell sub-
strates [25].
The correct interpretation of the IF-ANA results is impor-
tant and must always be correlated with the patient's
symptoms and signs. While reporting IF-ANA three
parameters are evaluated; these include the pattern of flu-
orescence, substrate used and the titer of a positive test. A
negative IF-ANA result essentially excludes possibility of
active CTD.
Fluorescence patterns and intensity
Different staining patterns are reported which give clues as
to the significance of the ANA and type of CTD (table 3,
figure 1):
1. Nuclear patterns: homogeneous, speckled (fine and
coarse), peripheral/rim, nucleolar, centromeric, PCNA
(proliferating cell nuclear antigen), nuclear dots, nuclear
membrane, diffuse grainy.
2. Cytoplasmic patterns: speckled, mitochondrial-like,
ribosomal-like, Golgi apparatus, lysosomal-like, cytoskel-
etal filaments (actin, vimentin, cytokeratin)
3. Mitotic patterns: mitotic spindle, centrosomes, NuMA
(nuclear mitotic apparatus), midbody, CENP-F (centro-
mere protein)
Among these homogenous, speckled, peripheral and
nucleolar patterns are more commonly observed and of
clinical importance. With any of these fluorescence pat-
terns intensity of staining with a qualitative scale of values
from + to ++++ should also be reported as fluorescence
intensity is generally proportional to antibody concentra-
tion and predicts the severity of the CTD.
ANA substrate
Sera of some patients with SLE may be negative on animal
substrates i.e. mouse kidney or rat liver but are positive on
human substrate i.e. Hep-2 cell lines [26-28]. Due to var-
Table 2: Significance of positive ANA test in CTD and some non-autoimmune conditions [36]
Useful for diagnosis Useful for monitoring or prognosis
1) Lupus erythmatosus (LE) 1) Juvenile chronic oligoarticular arthritis
SLE 2) Raynaud phenomenon
Discoid LE Not useful for diagnosis
Subacute cutaneous LE
Neonatal LE 1) Relatives of patients with CTD
Overlap of two or more LE subsets 2) Other autoimmune diseases (e.g., Rheumatoid arthritis, 
Idiopathic thrombocytopenia purpura, primary biliary cirrhosis, 
autoimmune thyroiditis)
Overlap of LE with other CTD 3) Drugs (e.g., procainamide, hydralazine)
2) SS 4) Silicone breast implant patients
Cutaneous SS (morphea) 5) Fibromyalgia
Systemic SS 6) Chronic infections
a) Limited disease 7) Neoplasms
b) Diffuse disease 8) Elderly persons
3) PM/Dermatomyositis 9) Pregnant women
4) Sjögren's syndrome (primary and secondary) 10) Healthy persons
5) Mixed CTD
6) Overlap and undifferentiated CTD
Diagrammatic representation of common nuclear patterns  observed under fluorescence microscopy Figure 1
Diagrammatic representation of common nuclear 
patterns observed under fluorescence microscopy.Diagnostic Pathology 2009, 4:1 http://www.diagnosticpathology.org/content/4/1/1
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iable sensitivity with the substrate used it is essential to
report the type of substrate being used by the lab.
ANA titer
It is directly proportional to antibody concentration and
expressed with a quantitative scale of values. Its evalua-
tion is crucial as low titer is less significant than a high titer
and may be seen even in healthy individuals. There are
many studies which have attempted to determine the
optimum screening dilution of sera for ANA testing. A
titer of 1:160 is taken as significant for the diagnosis of
CTDs in majority of laboratories [29,30].
Although IF-ANA test is widely used and considered to be
gold standard still the results may sometimes be misinter-
preted. As it detects several different antibodies cross-reac-
tions can occur. In up to 3% of the normal population it
can give false positive result. Also ANA levels tend to rise
when symptoms flare and fall, often being undetectable,
when symptoms are mild or patient is in remission. More-
over each CTD has specific antibody associated with it and
sometimes it is difficult to specify or categorize an autoan-
tibody [31,32]. Certain patterns i.e. nucleolar and centro-
meric are less well defined by IF-ANA tests. The test
therefore is mainly used for screening rather than to diag-
nose a CTD.
EIA/ELISA
There are two types of EIA or ELISA methods currently
used for ANA testing. One is called generic assay which
detects ANA of broad specificity similar to IF-ANA and
other is antigen specific assay that detects ANA and reacts
with a single autoantigen i.e. dsDNA, SS-A/Ro, SS-B/La,
Scl-70, Sm, Sm/RNP etc. In antigen specific assay multiple
antigens are coated on to microtitre plates, usually a com-
bination of SSA/Ro, SSB/La, Sm, and U1-RNP, with many
also including Jo-1 and Scl70. This new test is both highly
specific and sensitive and substantially decreases the time
involved when screening large numbers of patient sam-
ples. The test is simple to perform, can be automated and
does not require highly trained operators who can recog-
nize microscopic patterns. The EIA/ELISA is therefore
becoming the most widely used method not only for rou-
tine screening but also for detection of specific ANA. Kits
available in the market either utilize extracts of tissue con-
taining various nuclear components or molecules synthe-
sized by recombinant technology. The later may include
individual recombinant molecules such as SS-A/Ro, or
combinations of molecules which increase the sensitivity
of the test. In a recent study, the performance of ELISA test
was compared with the "gold standard" IF-ANA test. The
agreement that a serum is ANA positive was 87% to 95%
when comparing the ELISA and IF-ANA test results [33].
The sensitivity of the various ELISAs was 69% to 98% and
the specificity ranged between 81% and 98%. These fig-
ures were arrived at using sera that were positive at 1:160
by the IF-ANA test. The above comparison figures were
much lower for sera with IF-ANA titer of 1:40.
Although the second multicentre European study showed
that ELISA methods are improving [34], the recent study
by Bizzaro et al suggests that the problem of false positive
results in ELISA is still widespread [35]. ELISA may miss
anti-SSA/Ro even when using the reference sera. This is
probably a result of the vigorous antigen preparation
methods. Sera that react only with conformational anti-
gens can also miss the presence of antigen. The ELISA
techniques have also been found to miss a low titer posi-
tive ANA as well as sera with specific ANA. Presently,
ELISA tests therefore may be adequate to screen sera only
with intermediate to high titers. It remains to be seen from
further studies whether the performance of screening ANA
tests by ELISA would match that by the fluorescent tech-
nique [36].
Techniques used for detection of specific ANA
Detection of antibodies against dsDNA
Three techniques are currently in use for the detection of
anti-dsDNA antibodies:
1) IF-ANA test using Crithidia luciliae as the substrate
(CLIF)
2) The Farr assay
3) ELISA dsDNA
CLIF
Aarden and his colleagues in 1975 used IF-ANA test for
detection of dsDNA antibodies by using a haemoflagellate
Table 3: Common IF-ANA patterns associated with specific diseases
ANA pattern Antigen Associated diseases
Speckled ENA, RNP, Sm, SSA/Ro, SSB/La, Scl-70, Jo-1, ribosomal-P SLE, Mixed CTD, SS, Primary Sjogren's syndrome, PM
Homogenous dsDNA, Histones SLE, Drug induced SLE
Peripheral (rim) RNP, Sm, SSA/Ro SLE, SS
Nucleolar Anti-PM-Scl, anti-RNA polymerase I-III, anti-U3-RNP, To RNP SS, PM
Centromere CENP A-E Limited SSDiagnostic Pathology 2009, 4:1 http://www.diagnosticpathology.org/content/4/1/1
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C. luciliae as the substrate [37]. The organism is related to
trypanosomes and is equipped with an intracellular
organelle, the kinetoplast. The kinetoplast contains
dsDNA in high concentration while apparently not con-
taining any other recognizable nuclear antigens. The test
is most useful in primary diagnosis of SLE with high spe-
cificity when compared to ELISA [38].
Although the sensitivity is comparable to Farr assay, CLIF
is easy to perform, possesses an intrinsic check on the
immunoglobulin character of the DNA-binding activity,
determines the Ig classes and subclasses of antibodies to
DNA. In addition, there is an absence of interference with
antibodies to single-stranded DNA [39].
Farr assay
The Farr assay is a radio-labeled assay which quantifies
antibody to a given antigen in sera through precipitation
of antibody-antigen complexes on addition of ammo-
nium sulfate at high concentration. A radio-labeled anti-
gen (dsDNA) allows the quick determination of
proportion of the antibody in the precipitate. The Farr
assay is quite specific and has been advocated as the most
reliable assay. However, it is time-consuming, technically
difficult and involves the use of radioactive material [40].
Detection of autoantibodies against ENA
Gel precipitation assays
Techniques of precipitating antibodies to ENA were dis-
covered and used as diagnostic tools in CTD almost 5 dec-
ades ago [40]. The early work relied mainly on gel based
techniques i.e. double immunodiffusion (DID) or coun-
ter current immunoelectrophoresis (CIE)) [41,42]. CIE
has been shown in several studies to be more sensitive
than DID [35,43]. These gel precipitation assays however
have some limitations. They are not quantitative and dis-
ease sensitivity is poor [31]. Therefore several other
approaches were explored, with the aim of increasing
assay sensitivity but without a loss of disease specificity.
Passive haemagglutination (PHA)
The PHA method was quite popular in the late 1970s but
has since been superseded by EIA/ELISA and western blot.
Analysis appears to have been restricted to anti-Sm and
anti-RNP antibodies. Although assay sensitivity is high,
some problems with specificity, in particular with differ-
entiating anti-Sm from anti-U1-RNP, have been described
[43].
Western (immuno) blot
Immunoblotting was introduced in the 1980s and has
been useful in refining our understanding of the spectrum
of ANA. In this method first the nuclear and cytoplasmic
antigens are separated according to their molecular weight
by polyacrylamide gel electrophoresis and then trans-
ferred onto a membrane or strips. Antigen containing
strips are incubated with control or patient serum. If
present in the serum, a particular ANA binds to the spe-
cific antigen on the strip. After repeated washing and incu-
bations with two types of conjugates and a chromogen
substrate, positive reactions are indicated by a band on the
strip. The specificity of the antibody is defined by the
identification of the positive bands in comparison with
the positive control strip. Although considered to be
highly sensitive for anti-ENA a major disadvantage with
this technique is that antibodies directed against confor-
mational epitopes are not detected [44]. In several studies,
immunoblotting was found to be particularly insensitive
for anti-SSA/Ro [34,45]. This apparent paradox is
explained by the fact that the higher resolution seen in
western blotting detects only linear epitopes whereas
some 15% of anti-SSA/Ro antibodies react only with con-
formational epitopes not detectable in western blot.
Moreover western blot is considered to be inadequate for
anti-Scl70 with an assay sensitivity of only 25% [35]. Also
sometimes there may be a problem with the under detec-
tion of U1-RNP [46,47]. Again, disease specificity is poor
and in studies on normal populations false positives are
not infrequent.
Dot blot
The dot blot method is a qualitative assay, which utilizes
strips of nitrocellulose on which purified antigens are
blotted at pre-located spots. The antigen sources used are
bovine and rabbit thymus (for SSA, Sm and Scl-70) or calf
spleen and rabbit thymus (for SSB and Sm/RNP). The
strips are incubated with a 50-fold dilution of patient
serum followed by incubation with an alkaline phos-
phatase-protein A conjugate. Finally the test strips are
stained with 5-bromo-4-chloro-3-indolylphosphate/
nitroblue tetrazolium. Positive strips are stained as a blue
spot [48]. The dot blot test is advantageous for time man-
agement as the test requires just 30 minutes, can be easily
performed and relatively cheaper. A major drawback how-
ever is the blotting of RNP antigen in combination with
Sm antigen. This implies that if both the Sm spot and the
Sm/RNP spot are positive the presence of Sm antibodies
alone cannot be distinguished from the combined pres-
ence of Sm and RNP antibodies.
Line blot Immunoassay
Line blot Immunoassay is another qualitative test which
reveals antibody reactivity to antigens that are applied as
distinct lines on a membrane. Specific nuclear antigens
are applied to nitrocellulose strips at equal distances. The
required number of strips is placed to the respective row
of the incubation tray. To rehydrate and to block free
binding sites against unspecific binding, the strips are
incubated with buffer, containing blocking protein. After
discarding the blocking buffer, the membrane strips areDiagnostic Pathology 2009, 4:1 http://www.diagnosticpathology.org/content/4/1/1
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incubated with prediluted serum samples. According to
their specificity, autoantibodies, if present in the sample
bind to the antigens are traced by alkaline phosphatase
conjugated anti-human-IgG antibodies and appear as
blue stained bands on the strips. Like dot blot, line blot is
also easy to use and requires less processing time and is
comparable to ELISA in sensitivity and specificity. Auto-
mated interpretation is also possible [49].
Multiplex Immunoassay (MIA)
The newly developed MIA enables the detection of multi-
ple specific ANA as separate entities at the same time [50-
53]. In MIA the patient sera is incubated in a well contain-
ing a multiplexed mixture of the bead suspension. The
bead suspension consists of polystyrene microspheres
that are conjugated with different antigens and nuclear
extract of Hep-2 cells. If the patient serum contains anti-
bodies to any of the antigens or Hep-2 nuclear extract, the
antibody will bind to the immobilized antigen on 1 or
more of the bead sets. The antibody-antigen-bead com-
plex is then incubated with phycoerythrin conjugated goat
anti-human IgG and the bead suspension is then analyzed
by the immunoassay analyzer. The beads are uniquely
identified by their corresponding fluorescent dye, and the
amount of phycoerythrin conjugate is determined for
each antigen. Multiplex ANA testing is being claimed to be
more efficient and technically less challenging than IF-
ANA screening, decreases false positivity, removes subjec-
tivity and is more efficient than conventional ELISA [51].
Flowcytometry
Flowcytometry with autoantigen-coated fluorescent beads
has been gaining popularity in recent years. It gives quan-
titative results based on reactivity with a mixture of bead
subsets that are each labeled with a unique combination
of internal fluorescent signal and antigen. Fluorescent
beads-based techniques, also commonly referred to as
Reflex ANA, are claimed to have multiple advantages such
as simultaneous testing for recognition of several anti-
gens, automation, cost effectiveness and high sensitivity.
However, most significant limitation of this method is
that it provides only a single result for each analysis.
Often, multiple tests are necessary in order to be able to
report a complete repertoire of required autoantibody
results [54,55].
Antigen microarray
Antigen microarray currently not widely performed but
may be an excellent advancement for simultaneous meas-
urement of multiple ANA. This is a nanotechnology tech-
nique in which pre-synthesized antigens are printed on
polystyrene and incubated with serum samples and then
with horseradish peroxidase-conjugated secondary anti-
bodies and chemiluminescent substrates. Light signals
produced are captured by a charge-coupled device camera
based chip reader. Antibodies are quantified by use of cal-
ibration curves [56]. The method offers the advantages of
complete automation, consistent performance, cost-effec-
tiveness and more precise measurement of antibody lev-
els. The results are largely comparable to those obtained
with techniques currently used in clinical laboratories
[57-59]. Microarray may also be suitable for the discovery
and evaluation of novel autoantibodies [60].
Among the above mentioned techniques choice depends
on multiple factors i.e. test required for screening or detec-
tion of specific ANA, sensitivity and specificity of the test,
availability, cost effectiveness, time taken and skill
required to perform the test. Advantages and disadvan-
tages for each of these tests have been compared in table 4.
Guidelines for detection of ANA
A positive ANA result in conjunction with clinical findings
is diagnostic therefore frequently asked by the clinician in
case of suspected CTD. Since different ANA are associated
with one or other CTD a systematic approach has to be
followed while performing these tests. Therefore initially
screening is carried out usually by IF-ANA/ELISA and if
positive more specific tests are performed based on clini-
cal findings and IF-ANA staining patterns (table 3).
Autoantibody to dsDNA is specific and diagnostic for SLE
and levels are elevated during active disease. Therefore in
a case of suspected SLE if homogenous pattern is observed
on IF-ANA further tests i.e. CLIF, ELISA, blotting tests etc.
may be done to confirm dsDNA. Similarly anti-Sm is
highly specific for SLE and needs confirmation by other
tests i.e. Blotting etc. but is present in only 10% of SLE
cases.
Anti-SSA/Ro antibody although more common in
Sjogren's syndrome but can also be found in 30% cases of
SLE with cutaneous involvement. Therefore if IF-ANA
shows speckled/peripheral pattern further tests i.e. Blot-
ting, MIA are required for detection of anti-SSA/Ro anti-
body. Clinical significance and detection methods for
anti-SSB/La are similar to that for anti-SSA/Ro except that
it is less common and may indicate minor course of dis-
ease. While presence of these two autoantibodies supports
Sjogren's syndrome they are not much needed for diagno-
sis. Anti-Scl-70 autoantibody found in scleroderma (SS)
gives a fine speckled staining pattern on IF-ANA and can
be confirmed by immunodiffusion techniques but its
detection is also not a necessity for diagnosis.
Antinucleolar antibodies are a group of autoantibodies
which give nucleolar staining pattern. Most common of
these are anti-PM-Scl, anti-RNA polymerase I-III and anti-
U3-RNP (antifibrillarin). Although seen in sclerodermaDiagnostic Pathology 2009, 4:1 http://www.diagnosticpathology.org/content/4/1/1
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and polymyositis (PM) their detection is also not widely
practiced [24].
A protocol generally followed by the clinicians and step
by step approach to detect all these autoantibodies has
been described in figure 2. A summary of certain other
guidelines [24,61] to be considered are:
- ANA testing is not helpful in confirming a diagnosis of
rheumatoid arthritis or osteoarthritis therefore should not
be used in such conditions.
- ANA testing is not recommended to evaluate fatigue,
back pain or other musculoskeletal pain unless accompa-
nied by one or more of the clinical features in favor of a
CTD.
- ANA testing should usually be ordered only once.
- Positive ANA tests do not need to be repeated.
- Negative tests need to be repeated only if there is a strong
suspicion of an evolving CTD or a change in the patient's
illness suggesting the diagnosis should be revised.
- A positive ANA test is important only in conjunction
with clinical evaluation and in the absence of symptoms
and signs of a CTD; a positive ANA test only confounds
the diagnosis. A positive ANA test can also be seen in
healthy individuals, particularly the elderly or in a wide
range of diseases other than CTD, where it has no diagnos-
tic or prognostic value.
Recommendations in the guidelines may further evolve
over time, as newer analytic methods and additional clin-
ical research yield important results.
In future!
The future for ANA detection looks very promising. We
have come a long way from the simplest test like LE cell
method to fully automated ELISAs to nanotechnology.
Future development will undoubtedly include more
sophisticated instrumentation with ultra sensitive detec-
tion, faster turnaround time, and increased throughput in
ANA detection. Advances in the new technologies like
multiplex immunoassays and antigen microarrays offer
an attractive alternative to traditional ELISA, immunob-
lot, and IFA techniques. Rapid development in the area of
quantum dots and other fluorescent nanoparticles will
Table 4: Performance of various tests used for detection of specific antibodies
Method Advantages Disadvantages
IF-ANA Cost effective
Easy to perform
High sensitivity and specificity
Time consuming
Can give false positive results
ENA categorization difficult
Requires trained personnel
ELISA Automated
Potential for quantification
High sensitivity
Potential for antibody class definition
Potential for false positives
Expensive
Requires purified antigen
DID Cost effective
High specificity
Detects multiple antibodies at a time
Low sensitivity
Subjective interpretation
Need for large volumes of prototype sera
CIE Cost effective
High specificity
Detects multiple antibodies at a time
Faster than double diffusion
Modest sensitivity
Subjective interpretation
Need for large volumes of prototype sera
PHA Semiquantitative
High specificity
Time consuming
Needs purified antigen
Western blot More sensitive than DID and CIE
High specificity
Expensive
Time consuming
Detects linear epitopes only
Dot/Line blot Easy to perform, rapid
High sensitivity and specificity
Automation possible
Qualitative
Distinction between certain antibodies difficult
MIA Detects multiple antibodies at a time
Quantitation possible
Expensive
Flowcytometry Cost effective
Automated
High sensitivity
Provides single result at a time
Microarray Detects multiple antibodies at a time
Complete automation possible
High sensitivity and specificity
Cost effective
Not widely availableDiagnostic Pathology 2009, 4:1 http://www.diagnosticpathology.org/content/4/1/1
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also eventually benefit routine clinical laboratory analy-
sis.
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